DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical Program
CUPERTINO, Calif., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain. Top line results from this study of patients undergoing arthroscopic shoulder surgery showed a consistent reduction of […]
DURECT Reports Positive Phase IIb Data from POSIDUR(TM) Clinical Program Read More »